naltrexone has been researched along with remifentanil in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Aceto, MD; Coop, A; Harris, LS; May, EL; Metcalf, MD; Traynor, JR; Woods, JH | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bilotta, JM; Brackeen, MF; Feldman, PL; James, MK; Leighton, HJ; Schuster, SV | 1 |
| Schwab, CA; Wright, DA | 1 |
| Fantegrossi, WE; Koreeda, M; Kugle, KM; Valdes, LJ; Woods, JH | 1 |
| Mohan, S; Stevens, CW | 1 |
| Chen, TY; Gomery, P; Israel, R; Rosow, CE; Stambler, N; Stefanovich, P | 1 |
| Irwin, MG; Jiang, LL; Li, R; Wong, GT | 1 |
| Cabañero, D; Campillo, A; García-Nogales, P; Puig, MM; Romero, A | 1 |
| Brosnan, RJ; Ilkiw, JE; Pypendop, BH | 1 |
| Jeong, C; Jeong, H; Jeong, S; Kim, SJ; Lee, J; Lee, S; Yoo, KY | 1 |
| Ahlstrand, R; Magnuson, A; Savilampi, J; Wattwil, M | 1 |
| Ko, MC; Lagorio, CH; Sukhtankar, DD | 1 |
| Hu, N; Li, Y; Shu, R; Wang, C; Wang, G; Wang, H; Xie, K; Yu, Y; Zhang, L | 1 |
| Ehrich, E; Sellers, EM; Shram, MJ; Silverman, B; Turncliff, R | 1 |
| Coggiano, M; Hiranita, T; Katz, JL; Mereu, M; Quarterman, JC; Tanda, G | 1 |
| Bradberry, CW; Panlilio, LV; Schindler, CW; Secci, ME | 1 |
| Cajander, P; Cock, C; Magnuson, A; Omari, T; Savilampi, J; Scheinin, M | 1 |
1 review(s) available for naltrexone and remifentanil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for naltrexone and remifentanil
| Article | Year |
|---|---|
Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone.
Topics: Adult; Analgesics, Opioid; Cross-Over Studies; Double-Blind Method; Humans; Infusions, Intravenous; Male; Middle Aged; Miosis; Muscle Contraction; Naloxone; Naltrexone; Narcotic Antagonists; Piperidines; Quaternary Ammonium Compounds; Remifentanil; Treatment Outcome; Urinary Bladder; Urinary Retention; Urination | 2007 |
Use of naltrexone to antagonize high doses of remifentanil in cats: a dose-finding study.
Topics: Analgesics, Opioid; Animals; Cat Diseases; Cats; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Overdose; Female; Hyperkinesis; Naltrexone; Narcotic Antagonists; Piperidines; Prospective Studies; Remifentanil | 2011 |
Effects of remifentanil on the esophagogastric junction and swallowing.
Topics: Adult; Anesthetics, Intravenous; Cross-Over Studies; Data Interpretation, Statistical; Deglutition; Double-Blind Method; Esophagogastric Junction; Female; Humans; Male; Manometry; Naltrexone; Narcotic Antagonists; Piperidines; Quaternary Ammonium Compounds; Receptors, Opioid, mu; Remifentanil; Stomach; Young Adult | 2013 |
Use of Remifentanil in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent μ-Receptor Antagonist.
Topics: Adult; Analgesics, Opioid; Double-Blind Method; Female; Humans; Male; Middle Aged; Miosis; Naltrexone; Narcotic Antagonists; Piperidines; Receptors, Opioid, mu; Remifentanil; Visual Analog Scale; Young Adult | 2015 |
Effects of remifentanil on pharyngeal swallowing and esophageal motility: no impact of different bolus volumes and partial antagonism by methylnaltrexone.
Topics: Adult; Analgesics, Opioid; Deglutition; Drug Antagonism; Esophagus; Female; Healthy Volunteers; Humans; Injections, Intravenous; Male; Muscle Contraction; Muscle Relaxation; Naltrexone; Narcotic Antagonists; Pharynx; Quaternary Ammonium Compounds; Remifentanil | 2021 |
14 other study(ies) available for naltrexone and remifentanil
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
The influence of esters and carboxylic acids as the N-substituent of opioids. Part 1: Benzomorphans.
Topics: Analgesics, Opioid; Benzomorphans; Carboxylic Acids; Esters; Molecular Structure; Stereoisomerism; Structure-Activity Relationship | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues.
Topics: Alkylation; Animals; Enkephalin, Leucine; Guinea Pigs; Ileum; Kinetics; Male; Mice; Mice, Inbred Strains; Muscle Contraction; Muscle, Smooth; Naloxone; Naltrexone; Narcotic Antagonists; Piperidines; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu; Remifentanil; Vas Deferens | 1991 |
Intraoperative high-dose remifentanil in a patient on naltrexone therapy.
Topics: Aged; Analgesics, Opioid; Arteriovenous Fistula; Debridement; Female; Foot Ulcer; Humans; Intraoperative Complications; Naltrexone; Narcotic Antagonists; Piperidines; Remifentanil; Substance Withdrawal Syndrome | 2000 |
Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Benzeneacetamides; Diterpenes; Diterpenes, Clerodane; Hallucinogens; Male; Mice; Naloxone; Naltrexone; Narcotic Antagonists; Piperidines; Psychotropic Drugs; Pyrrolidines; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Remifentanil | 2005 |
Systemic and spinal administration of the mu opioid, remifentanil, produces antinociception in amphibians.
Topics: Acetic Acid; Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Injections, Spinal; Injections, Subcutaneous; Models, Animal; Naltrexone; Narcotic Antagonists; Pain; Pain Measurement; Piperidines; Rana pipiens; Receptors, Opioid, mu; Remifentanil; Time Factors | 2006 |
Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation.
Topics: Analgesics, Opioid; Animals; Blood Pressure; Cardiotonic Agents; Dose-Response Relationship, Drug; Heart Rate; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Naltrexone; Narcotic Antagonists; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Remifentanil; Somatostatin | 2010 |
Delayed postoperative latent pain sensitization revealed by the systemic administration of opioid antagonists in mice.
Topics: Animals; Dizocilpine Maleate; Dynorphins; Hyperalgesia; Male; Mice; Naloxone; Naltrexone; Narcotic Antagonists; Pain; Pain Threshold; Piperidines; Postoperative Complications; Reaction Time; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid, kappa; Remifentanil; Spinal Cord | 2011 |
Neuroprotective effects of remifentanil against transient focal cerebral ischemia in rats.
Topics: Anesthetics, Intravenous; Animals; Blood Pressure; Blotting, Western; Carbon Dioxide; Dose-Response Relationship, Drug; Infarction, Middle Cerebral Artery; Interleukin-6; Ischemic Attack, Transient; Male; Mitogen-Activated Protein Kinases; Naltrexone; Narcotic Antagonists; Nervous System Diseases; Neuroprotective Agents; Piperidines; Rats; Rats, Sprague-Dawley; Remifentanil; Reperfusion Injury; Tumor Necrosis Factor-alpha | 2012 |
Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats.
Topics: Animals; Azabicyclo Compounds; Benzimidazoles; Dose-Response Relationship, Drug; Male; Naltrexone; Narcotic Antagonists; Nociceptin Receptor; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Receptors, Opioid, mu; Reinforcement, Psychology; Remifentanil; Self Administration; Substance-Related Disorders | 2014 |
Inhibition of DOR prevents remifentanil induced postoperative hyperalgesia through regulating the trafficking and function of spinal NMDA receptors in vivo and in vitro.
Topics: Anesthetics, Intravenous; Animals; Disease Models, Animal; Hot Temperature; Hyperalgesia; Lumbar Vertebrae; Male; Naltrexone; Narcotic Antagonists; Oligopeptides; Pain Threshold; Pain, Postoperative; Piperidines; Posterior Horn Cells; Random Allocation; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid, delta; Remifentanil; Spinal Cord; Tissue Culture Techniques; Touch | 2015 |
Lack of Specific Involvement of (+)-Naloxone and (+)-Naltrexone on the Reinforcing and Neurochemical Effects of Cocaine and Opioids.
Topics: Analgesics, Opioid; Anesthetics; Animals; Brain; Cocaine; Conditioning, Operant; Discrimination, Psychological; Dopamine; Extinction, Psychological; Male; Microdialysis; Naloxone; Naltrexone; Narcotic Antagonists; Piperidines; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Remifentanil; Self Administration; Time Factors | 2016 |
Choice between delayed food and immediate opioids in rats: treatment effects and individual differences.
Topics: Analgesics, Opioid; Animals; Behavior, Addictive; Choice Behavior; Conditioning, Operant; Delay Discounting; Dose-Response Relationship, Drug; Feeding Behavior; Individuality; Injections, Intravenous; Male; Naltrexone; Oxycodone; Piperidines; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Remifentanil; Reward; Self Administration; Time Factors | 2017 |